comparemela.com
Home
Live Updates
Key Cardio Metabolic - Breaking News
Pages:
Latest Breaking News On - Key cardio metabolic - Page 1 : comparemela.com
In Akero Therapeutics Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
50mg (41%) and 28mg (39%) groups demonstrated =1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution
United states
Sarah oconnell
Andrew cheng
Linkedinand twitterfor
Stephen harrison
Christina tartaglia
Pa fibroscan
Exchange commission
Akero therapeutics inc
Pinnacle clinical research
Liver fat
Key markers
Change from baseline
Fat fraction
Key cardio metabolic
Conference call
vimarsana © 2020. All Rights Reserved.